Hiroshi Watanabe Citi has initiated coverage of Akero Therapeutics ( NASDAQ: AKRO ) at buy saying that its key pipeline candidate efruxifermin for metabolic dysfunction-associated steatohepatitis (MASH) could represent best-in-disease treatment potential. The investment bank has a $65 price target (~131% upside based on Nov. 15 close).
.
